Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by fredgoodwinsonon Apr 09, 2020 4:05pm
80 Views
Post# 30895652

RE:RE:RE:RE:Into reverse

RE:RE:RE:RE:Into reversePrecisely SB - 'Into Reverse' because the momentum was entirely reversed yesterday.

Neurosis/paranoia after long periods of silence/delay in anticipated information and entirely contradictory trading patterns are nothing new and in fact par for the course with this stock. Right now this unsettling trading comes very close to a due update.
 
The extent to which this may reflect underlying issues with the Trial remains to be seen - it certainly did in Phase I - but as you say those all appeared to have been addressed and this confirmed by uniformly positive subsequent advice. It is a Trial though and you never know.

IMHO and as already stated the Quarterly - good or bad news - should have been issued when due and prior to the current sell off. 


Bullboard Posts